Xinlitai class 1 new blood pressure lowering drug is approved, which is said to be beneficial to impact the medical insurance catalogue in the industry

Xinlitai (002294 SZ) announced on the evening of the 24th that the company's class 1 new blood pressure lowering drug alisartan ester tablet, which has attracted the market's attention, has obtained the production approval at present The insiders believe that the approval of this product at this time will help xinlitai strive for more time to impact the medical insurance catalog, generate benefits in advance, and thicken the performance of next year Analysts from many securities companies said that the approval of the upcoming revision of the medical insurance catalog is certainly good for the company, which is conducive to the company's preparation and increase the recognition of doctors for products In fact, since the third quarter of xinlitai, it has started the academic foreshadowing work in the early stage of the listing of alisartan ester tablets, mainly in the hospital for academic promotion, so that doctors can understand the indications and effects of the products The relevant person in charge of the company has repeatedly said that the products approved by the end of the year can catch up with the provincial non-basic drug bidding, and have the opportunity to impact the national and local medical insurance With the company's sales capacity, it is expected to exceed Taijia to become at least one billion varieties of the company in the future Alisartan ester tablet is a class 1.1 new drug independently developed by Shanghai ALIS Pharmaceutical Technology Co., Ltd., a domestic manufacturer, with a patent protection period up to 2026 In October 2012, xinlitai purchased the preparation production technology related to alisartan ester for 340 million yuan Jiangsu ALIS (a wholly-owned subsidiary of Shanghai ALIS) is responsible for the production of alisartan ester API, and xinlitai is responsible for the production and sale of alisartan ester tablets As a new antihypertensive drug, alisartan kamedoxomil is not less effective than losartan potassium, and has earlier onset, better antihypertensive consistency and less fluctuation in different treatment time In 2009, the global sales of losartan potassium and its compound preparations were about 3.6 billion US dollars.